Evaluation of Telemedicine Experience: Artificial Intelligence in Cancer Care

Background. To date, one of the key tasks of our time, which has yet to be solved, is to provide medical services remotely using constantly advancing information and communication technologies. It is medical sciences that urgently needs ICT tools for various scopes: providing medical care in remote regions, organizing continuous education of medical personnel, managing electronic patient records, implementing mobile diagnostic devices, and managing network of branches or medical facilities at the institutional level. Telemedicine is a necessity, especially for patients with comorbid chronic diseases like cancer.

Objective. To evaluate utilization of digital technologies at various stages of cancer care, through the example of artificial intelligence.

Materials and methods. A systematic literature review was conducted using PRISMA. The search was carried out in such databases as Elibrary, PubMed, MEDLINE, Google Scholar by keywords “Telemedicine in oncology”, “COVID-19 in oncology”, “Artificial Intelligence”, “Digital Technologies”, “Data Personalization”, and “Teleoncology”. Publications not primarily focused on evaluating telemedicine technologies in oncology were excluded from the review process.

Results. The literature review was conducted to consider the rapid integration of telemedicine since the pandemic, the risks associated with the widespread use of telemedicine in oncology, and the use of artificial intelligence in oncology, including the early detection and diagnosis of cancer. In conclusion, it is noted that the digitalization of healthcare radically changes the clinical workflow by expanding the possibilities for obtaining information from both medical staff and patients. Experience-based medicine is being replaced by an evidence-based, patient-centered approach. The rapidly developing artificial intelligence technologies will continue to have a great impact on the oncology in the near future. Both medical staff and scientific community must be prepared for the coming changes.

1. Volkova O.A., Budarin S.S., Smirnova E.V., Elbek Y.V. Experience in the use of telemedicine technologies in healthcare systems of foreign countries and the Russian Federation: a systematic review // Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021. №. 4. Pp. 73–85. (In Russ.)

2. Kamecka K., Foti C., Gawiński Ł., Matejun M., Rybarczyk-Szwajkowska A., Kiljański M., Krochmalski M., Kozłowski R., Marczak M. Telemedicine Technologies Selection for the Posthospital Patient Care Process after Total Hip Arthroplasty // Int J Environ Res Public Health. 2022 Sep 13; 19(18):11521. doi: 10.3390/ijerph191811521. (In Eng.)

3. Dorsey E.R., Topol E.J. Telemedicine 2020 and the next decade // Lancet. 2020; 395:859. doi: 10.1016/S01406736(20)30424-4. (In Eng.)

4. Gogia S. Rationale, history, and basics of telehealth // In: Gogia S., Masucci S., editors. Fundamentals of Telemedicine and Telehealth. Academic Press; Cambridge, MA, USA: 2020. Pp. 11–34. (In Eng.)

5. De Araújo №vaes M. Chapter 10—Telecare within Different Specialties in Fundamentals of Telemedicine and Telehealth // Gogia S., editor. Academic Press; Cambridge, MA, USA: 2020. Pp. 185–254. URL: https://www.sciencedirect.com/science/article/pii/B9780128143094000100 (accessed: 30.02.2024). (In Eng.)

6. Glinkowski W.M. Orthopedic Telemedicine Outpatient Practice Diagnoses Set during the First COVID-19 Pandemic Lockdown—Individual Observation // Int. J. Environ. Res. Public Health. 2022; 19:5418. doi: 10.3390/ijerph19095418. (In Eng.)

7. West HJ, Barzi A, Wong D. Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0? // Curr Oncol Rep. 2022 Dec;24(12):1843-1850. doi: 10.1007/s11912-022-01332-x. (In Eng.)

8. Lopez AM, Lam K, Thota R. Barriers and facilitators to telemedicine: can you hear me now? // ASCO Ed Book. 2021; 41:25–36. (In Eng.)

9. Shirke MM, Shaikh SA, Harky A. Implications of Telemedicine in Oncology during the COVID-19 Pandemic // Acta Biomed. 2020 Sep 7;91(3):e2020022. doi: 10.23750/abm.v91i3.9849. (In Eng.)

10. European Society for Medical Oncology. Cancer Patient Management During the COVID-19 Pandemic. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic (accessed: 30.02.2024). (In Eng.)

11. Sabesan S., Simcox K., Marr I. Medical oncology clinics through videoconferencing: an acceptable telehealth model for rural patients and health workers // Internal Medicine Journal. 2012; 42(7):780-785. (In Eng.)

12. Portnoy J., Waller M., Elliott T. Telemedicine in the Era of COVID-19 // The Journal of Allergy and Clinical Immunology: In Practice. 2020; 8(5):1489-1491. (In Eng.)

13. Panet F., Tétreault-Langlois M., Morin V., Sultanem K., Melnychuk D., Panasci L. The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature // Cancer Rep (Hoboken). 2022 Jul; 5(7):e1531. doi: 10.1002/cnr2.1531. (In Eng.)

14. Shimizu H., Nakayama KI. Artificial intelligence in oncology // Cancer Sci. 2020 May; 111(5):1452-1460. doi: 10.1111/cas.14377. (In Eng.)

15. Ohnstad HO., Borgen E., Falk RS., et al. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up // Breast Cancer Res. 2017; 19:120. (In Eng.)

16. Yeo SK., Guan JL. Breast cancer: multiple subtypes within a tumor? // Trends Cancer. 2017; 3:753-760. (In Eng.)

17. Shimizu H., Nakayama KI. A 23 gene-based molecular prognostic score precisely predicts overall survival of breast cancer patients // EBioMedicine. 2019; 46:150-159. (In Eng.)

18. Curtis C., Shah SP., Chin S-F., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups // Nature. 2012; 486:346-352. (In Eng.)

19. Bhinder B., Gilvary C., Madhukar NS., Elemento O. Artificial Intelligence in Cancer Research and Precision Medicine // Cancer Discov. 2021 Apr; 11(4):900-915. doi: 10.1158/2159-8290.CD-21-0090. (In Eng.)

20. Esteva A., Kuprel B., №voa RA., Ko J., Swetter SM., Blau HM., Thrun S. Dermatologist-level classification of skin cancer with deep neural networks // Nature. 2017; 542:115–118.

21. Jiang Y., Liang X., Wang W., Chen C., Yuan Q., Zhang X., et al. №ninvasive Prediction of Occult Peritoneal Metastasis in Gastric Cancer Using Deep Learning // JAMA Netw Open. 2021; 4:e2032269. (In Eng.)

22. McKinney SM., Sieniek M., Godbole V., Godwin J., Antropova N., Ashrafian H., et al. International evaluation of an AI system for breast cancer screening // Nature. 2020; 577:89–94. (In Eng.)